𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A randomised, double-blind, placebo-controlled, 5-weeks' study of org 3770 (mirtazapine) in major depression

✍ Scribed by M. C. Khan

Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
433 KB
Volume
10
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

✦ Synopsis

Fifty-four hospitalised and outpatients with a DSM 111 diagnosis of major depressive disorder and 21-item HPRSD score of 2 18, were randomised to 5 weeks' of treatment with either Org 3770 (n=27; 20-60mg/day) or placebo (n = 27). The treatment with Org 3770 resulted in statistically significant and clinically relevant differences over placebo at several assessment points and at endpoint. The differences favouring Org 3770 were present on the 17item HPRSD as well as the MADRS. Similar percentages of patients prematurely withdrew from the study. Adverse experiences were reported by 55% of the Org 3770-and 48% of the placebo-treated patients; the only meaningful difference between the two treatment groups is observed in numbers of patients complaining of dry mouth (8 vs 3 in the Org 3770-and placebo-treatment group, respectively). In conclusion, in this study Org 3770 was proven to be an effective and safe antidepressant.

📜 SIMILAR VOLUMES

Tianeptine and fluoxetine in major depre
Tianeptine and fluoxetine in major depression: a 6-week randomised double-blind study
✍ Vladimir Novotny; Frantisek Faltus 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB

In a 6-week, multicentre, randomised, double-blind controlled study, tianeptine (37.5 mg/day) and fluoxetine (20 mg/day) were compared for efficacy and safety in 178 patients with major depression. No significant difference was shown between the two drugs, either in terms of efficacy (MADRS, CGI, CO

Hypericum treatment of mild–moderate dep
Hypericum treatment of mild–moderate depression in a placebo–controlled study. A prospective, double–blind, randomized, placebo–controlled, multicentre study
✍ E. Schrader; B. Meier; A. Brattström 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 2 views

A prospective, randomized, multicentre, double-blind placebo controlled study is described which compares the ecacy and tolerability of hypericum administered as a concentrated ethanolic extract of St John's wort (ZE117) to patients with mild±moderate depression (ICD-10; F 32 . 0 mild; F 32 . 1 mode

A double blind, placebo-controlled pilot
A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression
✍ Paul E. Holtzheimer III; Thomas W. Meeks; Mary E. Kelley; Mustafa Mufti; Raymond 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 2 views

## Abstract ## Objective Depression in older adults is often associated with cognitive abnormalities and may predict later development of a primary cognitive disorder. This double‐blind, randomized, placebo‐controlled pilot study was designed to assess the safety and efficacy of galantamine augmen

Mirtazapine add-on therapy in the treatm
Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial
✍ Michael Berk; Clarissa S. Gama; Suresh Sundram; Harry Hustig; Les Koopowitz; Rus 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB 👁 1 views

## Abstract ## Objective Schizophrenia is a multifaceted illness with positive, negative and cognitive symptom domains. Standard treatments often focus on positive symptoms and may not adequately relieve other symptoms. Previous studies have suggested a role for mirtazapine in schizophrenia, parti

St. John's wort and Kava in treating maj
St. John's wort and Kava in treating major depressive disorder with comorbid anxiety: a randomised double-blind placebo-controlled pilot trial
✍ Jerome Sarris; David J. Kavanagh; Gary Deed; Kerry M. Bone 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 1 views

## Abstract ## Objective We report the first randomised controlled trial (RCT) using a combination of St. John's wort (SJW) and Kava for the treatment of major depressive disorder (MDD) with comorbid anxiety. ## Methods Twenty‐eight adults with MDD and co‐occurring anxiety were recruited for a d